QLife (QLIFE) Q2 2024 earnings summary

Executive summary

• Q2 2024 marked by significant legal and financial challenges, including the bankruptcy filing of Danish subsidiary Qlife ApS after losing an arbitration case, but operational progress continued in biomarker validation and clinical trials.

• The company is restructuring, focusing on reacquiring key assets and securing working capital to continue operations and pursue growth in the home-hospital diagnostics segment.

Financial highlights

• Revenue for Q2 2024 was KSEK 39, down from KSEK 46 in Q2 2023; no sales in Q1 2024.

• EBITDA improved to KSEK -8,002 from KSEK -16,287 year-over-year; net loss narrowed to KSEK -12,979 from KSEK -22,703.

• Cash flow for Q2 was KSEK -4,809, compared to KSEK 7,894 in Q2 2023; cash reserves at period end were KSEK 87, down from KSEK 9,396.

• Earnings per share before/after dilution for the quarter were SEK -0.01, compared to SEK -0.05 year-over-year.

• Shareholders' equity at June 30, 2024, was KSEK -28,549, compared to KSEK 103,230 a year earlier.

Outlook and guidance

• Focus remains on restructuring, securing capital, and reacquiring assets from the Danish subsidiary's estate.

• Continued operational support for Chinese partner Hipro and progress in clinical validation of new biomarkers, especially CRP and PKU.

• Anticipates further development in the rare disease segment and home-hospital diagnostics.